Plasminogen Activator Inhibitor-1 and Oncogenesis in the Liver Disease
Novel Combinatorial Therapeutic Targeting of PAI-1 (SERPINE1) Gene Expression in Alzheimer's Disease. | Semantic Scholar
PAI1 Monoclonal Antibody (242816) (MA5-23790)
Plasminogen Activator Inhibitor-1 and Oncogenesis in the Liver Disease
Cisplatin-activated PAI-1 secretion in the cancer-associated fibroblasts with paracrine effects promoting esophageal squamous cell carcinoma progression and causing chemoresistance | Cell Death & Disease
IJMS | Free Full-Text | Thrombin Upregulates PAI-1 and Mesothelial–Mesenchymal Transition Through PAR-1 and Contributes to Tuberculous Pleural Fibrosis
Biomolecules | Free Full-Text | The TGF-β1/p53/PAI-1 Signaling Axis in Vascular Senescence: Role of Caveolin-1
Possible interactions of PAI-1 with cell surface molecules and its... | Download Scientific Diagram
Pathways involved in the regulation of PAI-1 expression and function in... | Download Scientific Diagram
Drug Targeting of Plasminogen Activator Inhibitor-1 Inhibits Metabolic Dysfunction and Atherosclerosis in a Murine Model of Metabolic Syndrome | Arteriosclerosis, Thrombosis, and Vascular Biology
Development of a plasminogen activator inhibitor (PAI-1) assay and comparison of plasma PAI-1 activity in hyperlipidemic/dyslipidemic dogs with either hyperadrenocorticism or diabetes mellitus, and healthy dogs - ScienceDirect
LDR-Induced miR-30a and miR-30b Target the PAI-1 Pathway to Control Adverse Effects of NSCLC Radiotherapy: Molecular Therapy
PAI-1 and TGF-β | Arteriosclerosis, Thrombosis, and Vascular Biology